Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 2
1971 1
1972 1
1974 1
1979 1
1980 4
1982 1
1983 1
1986 5
1987 2
1988 2
1989 1
1990 2
1991 5
1992 3
1993 4
1994 4
1995 10
1996 3
1997 8
1998 2
1999 10
2000 4
2001 6
2002 10
2003 6
2004 7
2005 7
2006 7
2007 6
2008 6
2009 10
2010 14
2011 5
2012 11
2013 12
2014 5
2015 9
2016 13
2017 24
2018 8
2019 5
2020 3
2021 15
2022 19
2023 18
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Results by year

Filters applied: . Clear all
Page 1
Cardiomyopathy: An Overview.
Brieler J, Breeden MA, Tucker J. Brieler J, et al. Am Fam Physician. 2017 Nov 15;96(10):640-646. Am Fam Physician. 2017. PMID: 29431384 Free article. Review.
The definition and classification of cardiomyopathy have evolved considerably in recent years. Cardiomyopathy can be separated into primary (genetic, mixed, or acquired) and secondary categories, which result in varied phenotypes including dilated, hypertrophic …
The definition and classification of cardiomyopathy have evolved considerably in recent years. Cardiomyopathy can be separated …
Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M, Abbasi MA, Marar R, Geske JB, Gersh BJ, Anavekar NS. Ismayl M, et al. Curr Probl Cardiol. 2023 Jan;48(1):101429. doi: 10.1016/j.cpcardiol.2022.101429. Epub 2022 Sep 24. Curr Probl Cardiol. 2023. PMID: 36167226 Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unchanged for decades until the recent introduction of mavacamten, a first-in-class cardiac myosin inhibitor. ...Compared to placebo, mavacamte …
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unc …
Hypertrophic cardiomyopathy: a systematic review.
Maron BJ. Maron BJ. JAMA. 2002 Mar 13;287(10):1308-20. doi: 10.1001/jama.287.10.1308. JAMA. 2002. PMID: 11886323 Review.
CONTEXT: Throughout the past 40 years, a vast and sometimes contradictory literature has accumulated regarding hypertrophic cardiomyopathy (HCM), a genetic cardiac disease caused by a variety of mutations in genes encoding sarcomeric proteins and characterized by a …
CONTEXT: Throughout the past 40 years, a vast and sometimes contradictory literature has accumulated regarding hypertrophic cardio …
Mavacamten: First Approval.
Keam SJ. Keam SJ. Drugs. 2022 Jul;82(10):1127-1135. doi: 10.1007/s40265-022-01739-7. Epub 2022 Jul 8. Drugs. 2022. PMID: 35802255 Free PMC article. Review.
., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic dysfunction. ...
., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of d …
Recent successes in heart failure treatment.
Lam CSP, Docherty KF, Ho JE, McMurray JJV, Myhre PL, Omland T. Lam CSP, et al. Nat Med. 2023 Oct;29(10):2424-2437. doi: 10.1038/s41591-023-02567-2. Epub 2023 Oct 9. Nat Med. 2023. PMID: 37814060 Review.
Great strides have been taken in the treatment of specific cardiomyopathies such as cardiac amyloidosis and hypertrophic cardiomyopathy, whereby conditions once considered incurable can now be effectively managed with novel genetic and molecular approaches. ...
Great strides have been taken in the treatment of specific cardiomyopathies such as cardiac amyloidosis and hypertrophic cardiomyo …
Pheochromocytoma/paraganglioma-associated cardiomyopathy.
Szatko A, Glinicki P, Gietka-Czernel M. Szatko A, et al. Front Endocrinol (Lausanne). 2023 Jul 13;14:1204851. doi: 10.3389/fendo.2023.1204851. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37522121 Free PMC article. Review.
Catecholamine excess can manifest in several cardiovascular syndromes, including cardiomyopathy. PPGL-induced cardiomyopathies occur in up to 11% of cases and are most often associated with an adrenal pheochromocytoma (90%) and rarely with a paraganglioma derived from the …
Catecholamine excess can manifest in several cardiovascular syndromes, including cardiomyopathy. PPGL-induced cardiomyopathies occur …
Dilated cardiomyopathy: the complexity of a diverse genetic architecture.
Hershberger RE, Hedges DJ, Morales A. Hershberger RE, et al. Nat Rev Cardiol. 2013 Sep;10(9):531-47. doi: 10.1038/nrcardio.2013.105. Epub 2013 Jul 30. Nat Rev Cardiol. 2013. PMID: 23900355 Review.
Remarkable progress has been made in understanding the genetic basis of dilated cardiomyopathy (DCM). Rare variants in >30 genes, some also involved in other cardiomyopathies, muscular dystrophy, or syndromic disease, perturb a diverse set of important myocardial protei …
Remarkable progress has been made in understanding the genetic basis of dilated cardiomyopathy (DCM). Rare variants in >30 genes, …
Phenotyping in heart failure with preserved ejection fraction: A key to find effective treatment.
Zawadzka MM, Grabowski M, Kapłon-Cieślicka A. Zawadzka MM, et al. Adv Clin Exp Med. 2022 Oct;31(10):1163-1172. doi: 10.17219/acem/149728. Adv Clin Exp Med. 2022. PMID: 35581935 Free article. Review.
Specific therapies, such as tafamidis in transthyretin-related amyloidosis (ATTR) or mavacamten in hypertrophic cardiomyopathy, have demonstrated their efficacy. However, pathomechanisms leading to the development of different phenotypes of HFpEF seem more complex a …
Specific therapies, such as tafamidis in transthyretin-related amyloidosis (ATTR) or mavacamten in hypertrophic cardiomyopathy …
Current therapies for hypertrophic cardiomyopathy: a systematic review and meta-analysis of the literature.
Bayonas-Ruiz A, Muñoz-Franco FM, Sabater-Molina M, Oliva-Sandoval MJ, Gimeno JR, Bonacasa B. Bayonas-Ruiz A, et al. ESC Heart Fail. 2023 Feb;10(1):8-23. doi: 10.1002/ehf2.14142. Epub 2022 Oct 1. ESC Heart Fail. 2023. PMID: 36181355 Free PMC article. Review.
AIMS: The aim of this study was to synthesize the evidence on the effect of the current therapies over the pathophysiological and clinical characteristics of patients with hypertrophic cardiomyopathy (HCM). METHODS AND RESULTS: A systematic review and meta-analysis …
AIMS: The aim of this study was to synthesize the evidence on the effect of the current therapies over the pathophysiological and clinical c …
286 results